These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 17084173)
1. The case for early chemotherapy for the treatment of metastatic disease. Lucas A; Petrylak DP J Urol; 2006 Dec; 176(6 Pt 2):S72-5. PubMed ID: 17084173 [TBL] [Abstract][Full Text] [Related]
2. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587 [TBL] [Abstract][Full Text] [Related]
3. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Berry W; Eisenberger M Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869 [TBL] [Abstract][Full Text] [Related]
4. Doxetaxel: new indication. Prostate cancer: a few more weeks. Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096 [TBL] [Abstract][Full Text] [Related]
5. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Amato RJ; Teh BS; Henary H; Khan M; Saxena S Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115 [TBL] [Abstract][Full Text] [Related]
6. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Sava T; Basso U; Porcaro A; Cetto GL Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438 [TBL] [Abstract][Full Text] [Related]
7. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED; J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721 [TBL] [Abstract][Full Text] [Related]
8. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?]. El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344 [TBL] [Abstract][Full Text] [Related]
10. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. Berry WR Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076 [TBL] [Abstract][Full Text] [Related]
11. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141 [TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI; J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542 [TBL] [Abstract][Full Text] [Related]
13. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Petrylak DP Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271 [TBL] [Abstract][Full Text] [Related]
14. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Amato RJ; Hernandez-McClain J; Henary H Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for advanced prostate cancer: docetaxel and beyond. Dreicer R Hematol Oncol Clin North Am; 2006 Aug; 20(4):935-46, x. PubMed ID: 16861124 [TBL] [Abstract][Full Text] [Related]
16. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Oh WK; Tay MH; Huang J Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?". Ryan CJ; Eisenberger M J Clin Oncol; 2005 Nov; 23(32):8242-6. PubMed ID: 16278479 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for the treatment of hormone-refractory prostate cancer. Chowdhury S; Burbridge S; Harper PG Int J Clin Pract; 2007 Dec; 61(12):2064-70. PubMed ID: 17956560 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for non-hormone refractory prostate cancer. Winquist E Can J Urol; 2006 Feb; 13 Suppl 1():67-70. PubMed ID: 16526986 [TBL] [Abstract][Full Text] [Related]
20. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]